Xiangxue Pharmaceutical Co.,Ltd. (SHE:300147)
China · Delayed Price · Currency is CNY 6.80
+0.05 (0.74%)
Aug 4, 2026, 3:04 PM CST
Xiangxue Pharmaceutical Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 4,497 | 6,018 | 6,461 | 3,406 | 3,961 | 5,266 | |
Market Cap Growth | -15.21% | -6.86% | 89.71% | -14.02% | -24.79% | -9.85% |
Enterprise Value | 6,177 | 8,515 | 9,128 | 6,159 | 6,816 | 9,064 |
Last Close Price | 6.80 | 9.10 | 9.77 | 5.15 | 6.07 | 8.07 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Forward PE | - | 11.93 | 11.93 | 11.93 | 11.93 | 11.93 |
PS Ratio | 2.94 | 3.77 | 3.48 | 1.48 | 1.81 | 1.77 |
PB Ratio | -53.47 | 136.93 | 4.49 | 1.47 | 1.46 | 1.40 |
P/TBV Ratio | - | - | 437.03 | 4.23 | 3.47 | 3.20 |
P/FCF Ratio | 33.04 | 50.95 | - | 16.42 | - | - |
P/OCF Ratio | 28.81 | 43.10 | 355.48 | 12.93 | 17.42 | 20.45 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 4.04 | 5.34 | 4.91 | 2.68 | 3.12 | 3.05 |
EV/EBITDA Ratio | 53.71 | 97.14 | - | 21.82 | 113.06 | 72.50 |
EV/EBIT Ratio | - | - | - | 123.98 | - | - |
EV/FCF Ratio | 45.38 | 72.09 | - | 29.69 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | -17.09 | 33.38 | 1.56 | 1.05 | 0.90 | 0.92 |
Debt / EBITDA Ratio | 12.50 | 15.96 | - | 8.48 | 38.38 | 27.04 |
Debt / FCF Ratio | 10.56 | 12.42 | - | 11.73 | - | - |
Net Debt / Equity Ratio | -15.37 | 27.59 | 1.46 | 0.99 | 0.84 | 0.82 |
Net Debt / EBITDA Ratio | 11.67 | 13.83 | -163.18 | 8.09 | 38.01 | 24.64 |
Net Debt / FCF Ratio | 9.50 | 10.26 | -122.94 | 11.01 | -16.38 | -10.10 |
Asset Turnover | 0.22 | 0.22 | 0.24 | 0.27 | 0.22 | 0.25 |
Inventory Turnover | 3.41 | 3.69 | 3.86 | 3.54 | 2.69 | 2.78 |
Quick Ratio | 0.16 | 0.18 | 0.19 | 0.19 | 0.18 | 0.28 |
Current Ratio | 0.24 | 0.26 | 0.30 | 0.35 | 0.32 | 0.44 |
Return on Equity (ROE) | -217.95% | -184.89% | -45.91% | -15.96% | -15.58% | -16.45% |
Return on Assets (ROA) | -0.63% | -0.90% | -1.85% | 0.37% | -1.09% | -0.12% |
Return on Invested Capital (ROIC) | -10.67% | -4.26% | -5.75% | 1.03% | -2.96% | -0.31% |
Return on Capital Employed (ROCE) | -92.60% | -17.80% | -11.10% | 1.60% | -5.10% | -0.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | -31.49% | -23.14% | -13.29% | -11.42% | -13.38% | -13.07% |
FCF Yield | 3.03% | 1.96% | -0.26% | 6.09% | -3.53% | -5.79% |
Buyback Yield / Dilution | -0.63% | 0.10% | -0.18% | 0.50% | -0.09% | -0.89% |
Total Shareholder Return | -0.63% | 0.10% | -0.18% | 0.50% | -0.09% | -0.89% |